AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 30 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - U.S. government investigators at the National Institutes of Health say they have enhanced the tumor specificity of vaccinia virus in order to increase its effectiveness as an oncolytic agent and gene therapy vector.
The resulting construct, a mutant vaccinia virus devoid of thymidine kinase (TK[superscript]-) and vaccinia growth factor (VGF[superscript]-), could be used for therapies targeting rapidly dividing cells, a hallmark of tumor progression.
According to J. A. McCart and coinvestigators in the Surgery Branch at the NIH, they inserted enhanced green fluorescent protein into the viral construct, "creating a double-deleted mutant vaccinia virus (vvDD-GFP)."
When McCart and colleagues treated murine embryo NIH3T3 cells with vvDD-GFP, control wild-type vaccinia virus, or control parental TK[superscript]- and VGF[superscript]- viruses, viral recovery of vvDD-GFP was lower in resting cells and almost the same in dividing cells as in control-treated animals.
In similar intraperitoneal treatments of nude mice bearing tumors, vvDD-GFP was not recovered from normal brain tissues, but it was recovered from tumor cells. The other control viruses were recovered at varying levels in both brain and tumor tissues. In addition, mice receiving vvDD-GFP survived significantly longer than mice that received control viruses (Systemic cancer therapy with ...
Source: HighBeam Research, Mutant Vaccinia Virus Attacks Tumor Targets, Ignores Resting...